Completed PHASE1/PHASE2 INTERVENTIONAL NCT00140387

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)

Phase I/II Study of a Prime-Boost Schedule of Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®) in Hormone-naïve Prostate Cancer Patients

Sponsor: Cell Genesys

Conditions Prostate Cancer

Interventions Immunotherapy allogeneic GM-CSF secreting cellular vaccine

Updated 4 times since 2017 Last updated: Aug 30, 2005 Started: May 31, 1999 Completion: Mar 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00140387, this PHASE1/PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Cell Genesys, it has been updated 4 times since 1999, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

First recorded

May 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cell Genesys

Data source: Cell Genesys

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.